The histopathology of skeletal metastases

Bone Cancer

Volumn , Issue , 2010, Pages 243-250

  Tang, Ping ^a   Hicks, David G ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78049502756     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374895-9.00021-9     Document Type: Chapter

References (54)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer Statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
2. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
3. Cher M.L., Towler D.A., Rafii S., et al. Cancer interaction with the bone microenvironment. A workshop of the National Institutes of Health Tumor Microenvironment Study Section. Am J Pathol 2006, 168:1405-1412.
4. Hatoum H.T., Lin S.J., Smith M.R., et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases. Cancer 2008, 113:1438-1445.
5. Guise T.A. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008, 34(Suppl 1):S19-S24.
6. Coleman R.E., Guise T.A., Lipton A., et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the second Cambridge Conference. Clin Cancer Res 2008, 14:6387-6395.
7. Le Gall C., Bonnelye E., Clezardin O. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2008, 2:218-222.
8. Bonfil R.D., Fridman R., Mobashery S., et al. Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?. Curr Oncol 2008, 15:188-192.
9. Batson O.V. The function of the vertebral veins and their role in the spread of metastases. Ann Surg 1940, 112:138-149.
10. Masi L., Brandi M.L. Physiopathological basis of bone turnover. Q J Nucl Med 2001, 45:2-6.
11. Coleman R.E. Metastic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
12. Taube T., Elomaa I., Blomqvist C., et al. Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer. Bone 1994, 15:161-166.
13. Goltzman D. Osteolysis and cancer. J Clin Invest 2001, 107:1219-1220.
14. Roodman, G.D. N Engl J Med 2004, 350:1655-1664. Mechanisms of bone metastasis.
15. James J.J., Evans A.J., Pinder S.E., et al. Bone metastases from breast carcinoma: histopathological-radiological correlations and prognostic features. Br J Cancer 2003, 89:660-665.
16. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 1993, 13:443-449.
17. Guise T.A., Mohammad K.S., Clines G., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12:6213s-6216s.
18. Buijs J.T., van der Pluijm G. Osteotropic cancers: from primary tumor to bone. Cancer Lett 2008, 273:177-193.
19. Riethdorf S., Wikman H., Pantel K. Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008, 123:1991-2006.
20. Berrettoni B.A., Carter J.R. Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am 1986, 68:308-312. [Review].
21. Guise T.A. Molecular mechanisms of osteolytic bone metastases. Cancer 2000, 88:2892-2898.
22. Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone 1991, 12(Suppl 1):S9-S10.
23. Coleman R.E., Rubens R.D. The clinincal course of bone metastases from breast cancer. Br J Cancer 1987, 55:61-66.
24. Colleoni M., O'Neill A., Goldhirsch A., et al. Identifying breast cancer patients at high risk for bone metastases. J Clin Oncol 2000, 18:3925-3935.
25. Solomayer E.F., Diel I.J., Meyberg G.C., et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000, 59:271-278.
26. Bouizar Z., Spyratos F., Deytieux S., et al. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res 1993, 53:5076-5078.
27. Diel I.J., Solomayer E.F., Seibel M.J., et al. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 1999, 5:3914-3919.
28. Mihai R., Stevens J., McKinney C., et al. Expression of the calcium receptor in human breast cancer-a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol 2006, 32:511-515.
29. Tsuda H., Sakamaki C., Fukutomi T., et al. Squamoid features and expression of involucrin in primary breast carcinoma associated with high histological grade, tumour cell necrosis and recurrence sites. Br J Cancer 1997, 75:1519-1524.
30. Koyama T., Hasebe T., Tsuda H., et al. Histological factors associated with initial bone metastasis of invasive ductal carcinoma of the breast. Jpn J Cancer Res 1999, 90:294-300.
31. Smid M., Wang Y., Klijn J.G., et al. Genes associated with breast cancer metastatic to bone. J Clin Oncol 2006, 24:2261-2267.
32. Wei B., Wang J., Bourne P., et al. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor negative breast carcinomas. Hum Pathol 2008, 39:1809-1815.
33. Sleeman J.P., Cremers N. New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. Clin Exp Metastasis 2007, 24:707-715.
34. Bubendorf L., Schopfer A., Wagner U., et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31:578-583.
35. Carlin B.I., Andriole G.L. The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000, 88:2989-2994.
36. Roudier M.P., True L.D., Higano C.S., et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003, 34:646-653.
37. Whitmore W.J. Urol Clin North Am 1984, 11:205-220. Natural history and staging of prostate cancer.
38. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281:1591-1597.
39. Percival R.C., Urwin G.H., Harris S., et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987, 13:41-49.
40. Keller E.T., Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004, 91:718-729.
41. Roudier M.P., Morrissey C., True L.D., et al. Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 2008, 180:1154-1160.
42. J.P. Junior, M. Srougi, P.M. Borra, et al., E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer. Appl Immunohistochem Mol Morphol Aug 5 (2008) (Epub ahead of print).
43. Liao J., Li X., Koh A., et al. Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer 2008, 123:2267-2278.
44. Kollermann J., Weikert S., Schostak M., et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 2008, 26:4928-4933.
45. Dai J., Hall C.L., Escara-Wilke J., et al. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 2008, 68:5785-5794.
46. Muggia F.M., Hansen H.H. Osteoblastic metastases in small-cell (oat-cell) carcinoma of the lung. Cancer 1972, 30:801-805.
47. Hiraoka K., Zenmyo M., Watari K., et al. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008, 99:1595-1602.
48. Jemal A., Siegel R., Ward E., et al. Cancer Statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
49. Ljungberg B., Alamdari F.I., Rasmuson T., et al. Follow-up guidelines for non-metastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999, 84:405-411.
50. Hafez K.S., Novick A.C., Campbell S.C. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997, 157:2067-2070.
51. Janzen N.K., Kim H.L., Figlin R.A., et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843-852.
52. Shvarts O., Lam J.S., Kim H.L., et al. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 2004, 172:867-870.
53. RougraffB.T., Kneisl J.S., Simon M.A. Skeletal metastases of unknown origin. A prospective study of a diagnostic strategy. J Bone Joint Surg Am 1993, 75:1276-1281.
54. Didolkar M.S., Fanous N., Elias E.G., Moore R.H. Metastatic carcinomas from occult primary tumore. A study of 254 patients. Ann Surg 1977, 186:625-630.